However, patients at high risk of BC are not susceptible to AP.24534 (Ponatinib), AS601245 (JNK inhibitor), AZ628 (Raf inhibitor), AZD.2281 (Olaparib), AZD6244 (Selumetinib), CI.1040 (Mek inhibitor), Cytarabine, GDC.0449 (Vismodegib), Gemcitabine, JNK.9L, Lenalidomide, Nilotinib, PD.173074 (FGFR inhibitor), PD.0332991 (Palbociclib), PF.4708671 (S6 Kinase inhibitor), Pyrimethamine, Roscovitine (CDK inhibitor), SB590885 (B-Raf inhibitor) and Temsirolimus may have resistance. The gene discussed is BRAF; the disease is breast cancer.